Pralatrexate Induces Responses in Patients with Highly Refractory Peripheral T-Cell Lymphoma (PTCL).

被引：0

作者：

Pettengell, Ruth ^{[1
]}

Coiffier, Bertrand ^{[2
]}

Narayanan, Geetha ^{[3
]}

Hurtado de Mendoza, Fernando ^{[4
]}

Digumarti, Raghunadharao ^{[5
]}

Gomez, Henry ^{[6
]}

Zinzani, Pier Luigi ^{[7
]}

Schiller, Gary J. ^{[8
]}

Rizzieri, David A. ^{[9
]}

Cernohous, Paul ^{[10
]}

Wang, Lixia ^{[10
]}

Singer, Jack W. ^{[10
]}

机构：

[1] Univ London St Georges Hosp, London, England

[2] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France

[3] Reg Canc Ctr, Dept Med Oncol, Trivandrum 695011, Kerala, India

[4] Hosp Ddgardo Rebagliati Martins, Lima, Peru

[5] Nizams Inst Med Sci, Hyderabad, Andhra Pradesh, India

[6] Hosp Edgardo Rebagliati Martins, Lima, Peru

[7] Univ Bologna, Inst Hematol L&A Seragnoli, Dept Hematol Oncol, Bologna, Italy

[8] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA

[9] Duke Univ, Med Ctr, Durham, NC USA

[10] Cell Therapeut, Seattle, WA USA

来源：

BLOOD | 2009年 / 114卷 / 22期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：669 / 669

页数：1

共 50 条

[1] PRALATREXATE REVERSES THE TREND TO PROGRESSIVE RESISTANCE IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL)
Coiffier, B.
Zinzani, P.
Koutsoukos, A.
O'Connor, O.
ANNALS OF ONCOLOGY, 2011, 22 : 202 - 202
[2] Safety and Management of Pralatrexate Treatment in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL).
Pinter-Brown, Lauren
Horwitz, Steven M.
Pro, Barbara
Zinzani, Pier Luigi
Gisselbrecht, Christian
Cortelli, Barbara MacGregor
Fruchtman, Steven
O'Connor, Owen A.
BLOOD, 2009, 114 (22) : 668 - 668
[3] Pralatrexate in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL): Relationship between response and survival
Shustov, A. R.
Pro, B.
Horwitz, S. M.
Jacobsen, E. D.
Boyd, A.
Fruchtman, S. M.
O'Connor, O.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[4] Pralatrexate: Phase 1/2 Study in Japanese Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)
Maeda, Yoshinobu
Tobinai, Kensei
Nagai, Hirokazu
Nakane, Takahiko
Shimoyama, Tatsu
Nakazato, Tomonori
Sakai, Rika
Ishikawa, Takayuki
Izutsu, Koji
Ueda, Ryuzo
BLOOD, 2016, 128 (22)
[5] Pralatrexate injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma
Jennifer, Zhao C.
Sara Mohamed, Jaszczur
Salma, Afifi
Francine, Foss
EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (06) : 577 - 583
[6] PRALATREXATE IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA; REPORT ON THREE PATIENTS
Tezel, Pinar
Bulbul, Hale
Koseoglu, Fatos Dilan
Davulcu, Eren Arslan
Ulusoy, Yusuf
Soyer, Nur Akad
Sahin, Fahri
Tombuloglu, Murat
Saydam, Guray
LEUKEMIA RESEARCH, 2017, 61 : S51 - S51
[7] PROPEL: Results of the pivotal, multicenter, phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)
O'Connor, O.
Pro, B.
Pinter-Brown, L.
Popplewell, L.
Bartlett, N.
Lechowicz, M.
Savage, K.
Coiffier, B.
Saunders, M.
Horwitz, S.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[8] Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma
Marchi, Enrica
O'Connor, Owen A.
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2012, 3 (04) : 227 - 235
[9] Pralatrexate Is Effective In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) with Prior Ifosfamide, Carboplatin, and Etoposide (ICE)-Based Regimens
Goy, Andre
Pro, Barbara
Savage, Kerry Joanne
Bartlett, Nancy L.
Lechowicz, Mary Jo
Jacobsen, Eric D.
Young, Faith
Crump, Michael
Borghaei, Hossein
Link, Brian
Fruchtman, Steven M.
O'Connor, Owen A.
BLOOD, 2010, 116 (21) : 731 - 732
[10] Pralatrexate for Peripheral T-Cell Lymphoma (PTCL): Chance Only Supports The Prepared Mind
Altinay, Serdar
Kural, Alev
Ozmen, Aykut
Tural, Deniz
Tutar, Yusuf
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2023, 23 (03) : 298 - 305

← 1 2 3 4 5 →